So far, ICIs, such as anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) and anti-programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1), have emerged as the first-line MM treatment regimen. This evidence concerns the gene CTLA4 and Miyoshi myopathy.